Two drugs are better than one. A short history of combined therapy of ovarian cancer

Barbara Bukowska; Arkadiusz Gajek; Agnieszka Marczak

doi:10.5114/wo.2014.43975

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2015
vol. 19

Send email

Copy url:

abstract:

Review paper

Two drugs are better than one. A short history of combined therapy of ovarian cancer

Barbara Bukowska

,

Arkadiusz Gajek

,

Agnieszka Marczak

Contemp Oncol (Pozn) 2015; 19 (5): 350-353

DOI: https://doi.org/10.5114/wo.2014.43975

Online publish date: 2014/07/15

View full text Get citation

PlumX metrics:

Combined therapy of ovarian cancer has a long history. It has been applied for many years. The first drug which was commonly combined with other chemotherapeutics was cisplatin. It turned out to be effective given together with alkylating agents as well as with taxanes. Another drug which is often the basis of first-line therapy is doxorubicin.

The use of traditional chemotherapy is often limited due to side effects. This is why new drugs, targeted specifically at cancer cells (e.g. monoclonal antibodies or epidermal growth factor receptor inhibitors), offer a welcome addition when used in combination with conventional anticancer agents. Drugs applied in combination should be synergistic or at least additive. To evaluate the type of interaction between drugs in a plausible sequence, isobolographic analysis is used. This method allows one to assess whether the two agents could make an efficient combination, which might improve the therapy of ovarian cancer.

keywords:

Two drugs are better than one. A short history of combined therapy of ovarian cancer

Barbara Bukowska , Arkadiusz Gajek , Agnieszka Marczak

combined therapy, ovarian cancer, synergism, isobolographic analysis

Barbara Bukowska

,

Arkadiusz Gajek

,

Agnieszka Marczak